Copyright
©The Author(s) 2024.
World J Diabetes. Jun 15, 2024; 15(6): 1280-1290
Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1280
Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1280
Table 1 Clinical parameters of patients among normal controls, type 2 diabetes mellitus patients without peripheral vascular disease and type 2 diabetes mellitus patients with peripheral vascular disease
Clinical parameters | Normal controls (n = 63) | T2DM without PVD (n = 65) | T2DM with PVD (n = 57) | P value |
Age, yr | 53.29 ± 7.55 | 54.75 ± 7.72 | 56.73 ± 7.76 | 0.053 |
Male, n (%) | 31 (49) | 38 (58) | 38 (67) | 0.103 |
Height, cm | 164.84 ± 7.07 | 165.83 ± 8.61 | 164.20 ± 6.98 | 0.492 |
Weight, kg | 63.56 ± 10.09 | 68.95 ± 11.76a | 67.32 ± 11.35 | 0.021 |
BMI, kg/m2 | 23.33 ± 2.91 | 24.97 ± 3.12 | 24.89 ± 3.40a | 0.005 |
BSA, m2 | 1.67 ± 0.16 | 1.74 ± 0.19 | 1.71 ± 0.17 | 0.054 |
SBP, mmHg | 77.90 ± 0.57 | 82.17 ± 10.81a | 80.18 ± 10.58 | 0.001 |
DBP, mmHg | 123.38 ± 11.12 | 132.77 ± 16.29a | 130.70 ± 17.30a | 0.049 |
HR, bpm | 66.95 ± 8.61 | 75.58 ± 9.91a | 74.80 ± 8.20a | < 0.001 |
HbA1c, % | 5.48 ± 0.35 | 9.47 ± 2.39a | 9.94 ± 2.39a | < 0.001 |
TC, mmol/L | 4.53 ± 0.85 | 4.36 ± 1.06 | 4.55 ± 1.03 | 0.550 |
TG, mmol/L | 1.30 (0.89, 1.80) | 1.52 (0.93, 2.43) | 1.64 (1.01, 2.07) | 0.073 |
HDL-C, mmol/L | 1.25 ± 0.33 | 1.08 ± 0.29 | 1.08 ± 0.34 | 0.013 |
LDL-C, mmol/L | 2.65 ± 0.70 | 2.58 ± 0.84 | 2.70 ± 0.83 | 0.729 |
LPA, g/L | 0.17 (0.09, 0.29) | 0.12 (0.06, 0.32) | 0.16 (0.09, 0.25) | 0.772 |
FPG, mmol/L | 4.99 (4.57, 5.28) | 10.02 (7.44, 13.64)a | 10.25 (8.29, 14.07)a | < 0.001 |
BUN, mmol/L | 4.90 (3.60, 6.40) | 5.65 (4.70, 6.58) | 6.00 (4.70, 7.40)a | 0.015 |
SCr, μmol/L | 65.00 (56.00, 76.00) | 61.00 (51.75, 81.95) | 61.70 (52.20, 73.00) | 0.772 |
Medication (%) | ||||
ACEI/ARB | - | 13 (20) | 12 (21) | |
Calcium channel blocker | - | 10 (15) | 20 (35) | |
β-blocker | - | 1 (2) | 2 (4) | |
SGLT-2 inhibitor | - | 14 (22) | 19 (33) | |
Metformin | - | 36 (55) | 36 (63) | |
Insulin | - | 41 (63) | 42 (74) |
Table 2 Echocardiographic parameters among normal controls, type 2 diabetes mellitus patients without peripheral vascular disease and type 2 diabetes mellitus patients with peripheral vascular disease
Echocardiographic parameters | Normal controls (n = 63) | T2DM without PVD (n = 65) | T2DM with PVD (n = 57) | P value |
LAd, mm | 34.42 ± 2.76 | 35.47 ± 3.25 | 36.17 ± 3.82a | 0.015 |
IVSd, mm | 9.39 ± 0.74 | 9.20 ± 0.97 | 9.27 ± 0.97 | 0.477 |
LVPWd, mm | 9.05 ± 0.77 | 8.98 ± 0.99 | 9.13 ± 1.06 | 0.685 |
LVDd, mm | 46.35 ± 2.97 | 45.42 ± 3.60 | 46.60 ± 3.24 | 0.110 |
LVEDV, mL | 76.76 ± 14.89 | 74.02 ± 16.74 | 78.04 ± 15.98 | 0.358 |
LVESV, mL | 26.75 ± 6.53 | 26.12 ± 7.13 | 26.63 ± 6.47 | 0.857 |
LVEF, % | 65.19 ± 3.98 | 64.98 ± 3.39 | 65.81 ± 4.16 | 0.478 |
MAPSE, mm | 14.44 ± 1.49 | 14.16 ± 1.85 | 13.23 ± 1.87a,b | 0.001 |
E, m/s | 0.84 ± 0.13 | 0.75 ± 0.15a | 0.79 ± 0.13a | 0.001 |
A, m/s | 0.70 ± 0.15 | 0.74 ± 0.18 | 0.81 ± 0.17a,b | 0.002 |
E/A | 1.24 ± 0.28 | 1.08 ± 0.34a | 1.01 ± 0.27a | < 0.001 |
e′, m/s | 0.11 ± 0.02 | 0.09 ± 0.02a | 0.09 ± 0.02a | < 0.001 |
E/e′ | 8.09 ± 1.54 | 8.66 ± 1.53 | 9.45 ± 1.92a,b | < 0.001 |
Table 3 Layer-specific global longitudinal strain and peak strain dispersion among normal controls, type 2 diabetes mellitus patients without peripheral vascular disease and type 2 diabetes mellitus patients with peripheral vascular disease
Normal controls (n = 63) | T2DM without PVD (n = 65) | T2DM with PVD (n = 57) | P value | P trend | |
GLSepi, % | -18.65 ± 1.55 | -17.37 ± 1.85a | -16.92 ± 2.21a | < 0.001 | < 0.001 |
GLSmid, % | -21.57 ± 1.81 | -19.98 ± 2.08a | -19.47 ± 2.50a | < 0.001 | < 0.001 |
GLSendo, % | -25.03 ± 2.21 | -23.12 ± 2.43a | -22.72 ± 2.85a | < 0.001 | < 0.001 |
PSD, msec | 30.63 ± 7.29 | 35.03 ± 10.81a | 39.37 ± 12.42a,b | < 0.001 | < 0.001 |
Table 4 Receiver operating characteristic curve analysis for the detection the left ventricular systolic function in type 2 diabetes mellitus patients with peripheral vascular disease
ROC | GLSepi | GLSmid | GLSendo | PSD | Combined |
Sensitivity, % | 50.88 | 56.14 | 66.16 | 73.68 | 75.44 |
Specificity, % | 85.71 | 85.71 | 77.78 | 65.08 | 77.78 |
Youden index | 0.3659 | 0.4185 | 0.4094 | 0.3876 | 0.5322 |
AUC (95%CI) | 0.735 (0.647-0.811) | 0.753 (0.666-0.827) | 0.750 (0.663-0.825) | 0.735 (0.646-0.811) | 0.801 (0.719-0.869) |
Associated criterion | -17.0 | -19.8 | -23.5 | 32 | 0.44 |
P value | 0.064 | 0.127 | 0.103 | 0.050 |
Table 5 Correlation test in type 2 diabetes mellitus patients with peripheral vascular disease
Varibles | GLSepi | GLSmid | GLSendo | PSD | ||||
r value | P value | r value | P value | r value | P value | r value | P value | |
BMI | 0.089 | 0.510 | 0.093 | 0.491 | -0.009 | 0.945 | -0.017 | 0.900 |
HbA1c | -0.011 | 0.935 | 0.028 | 0.839 | -0.019 | 0.887 | -0.225 | 0.095 |
TC | 0.190 | 0.158 | 0.179 | 0.182 | 0.040 | 0.767 | 0.293 | 0.027 |
TG | -0.126 | 0.349 | -0.153 | 0.257 | -0.148 | 0.271 | 0.017 | 0.889 |
HDL-C | -0.033 | 0.812 | -0.029 | 0.834 | -0.165 | 0.228 | 0.093 | 0.499 |
LDL-C | 0.340 | 0.010 | 0.327 | 0.014 | 0.204 | 0.131 | 0.290 | 0.030 |
LPA | 0.159 | 0.254 | 0.134 | 0.339 | 0.184 | 0.187 | -0.103 | 0.465 |
BUN | 0.293 | 0.033 | 0.248 | 0.074 | 0.149 | 0.287 | 0.292 | 0.034 |
SCR | 0.301 | 0.027 | 0.264 | 0.053 | 0.166 | 0.231 | 0.205 | 0.137 |
LVEF | -0.434 | 0.001 | -0.439 | 0.001 | -0.447 | < 0.001 | -0.109 | 0.420 |
MAPSE | -0.248 | 0.063 | -0.313 | 0.018 | -0.260 | 0.051 | -0.111 | 0.411 |
Table 6 Intraclass correlation coefficients for intra- and inter-observer variability for layer specific global longitudinal strain and peak strain dispersion
Variable | Inter-observer variability | Intra-observer variability | ||
ICC | 95%CI | ICC | 95%CI | |
GLSendo | 0.955 | 0.887-0.982 | 0.964 | 0.910-0.986 |
GLSmid | 0.963 | 0.906-0.985 | 0.970 | 0.924-0.988 |
GLSepi | 0.960 | 0.900-0.984 | 0.970 | 0.925-0.988 |
PSD | 0.956 | 0.889-0.983 | 0.979 | 0.946-0.992 |
- Citation: Li GA, Huang J, Fan L. Evaluation of left ventricular systolic function in type 2 diabetes mellitus patients with and without peripheral vascular disease. World J Diabetes 2024; 15(6): 1280-1290
- URL: https://www.wjgnet.com/1948-9358/full/v15/i6/1280.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i6.1280